Cellectricon Signs Collaboration Agreement with AstraZeneca
Complete the form below to unlock access to ALL audio articles.
Cellectricon has announced collaboration with AstraZeneca, under which the companies will study the possibility of developing a cell-based microfluidic screening platform.
The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.
"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery," says Dr. Mattias Karlsson, VP Research & Development at Cellectricon.
"The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."
"We believe the Nanoflow system has the potential to expedite our efforts in ion channel drug discovery and we look forward to working in collaboration with Cellectricon," says Dr. Christer Nordstedt, VP Discovery Research Area CNS & Pain Control.
